Nanotechnology-based combinational drug delivery: an emerging approach for cancer therapy
P Parhi, C Mohanty, SK Sahoo - Drug discovery today, 2012 - Elsevier
Combination therapy for the treatment of cancer is becoming more popular because it
generates synergistic anticancer effects, reduces individual drug-related toxicity and …
generates synergistic anticancer effects, reduces individual drug-related toxicity and …
Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines
The discovery of new molecular targets and the subsequent development of novel
anticancer agents are opening new possibilities for drug combination therapy as anticancer …
anticancer agents are opening new possibilities for drug combination therapy as anticancer …
Polymeric nanoparticles with precise ratiometric control over drug loading for combination therapy
We report a novel approach for nanoparticle-based combination chemotherapy by
concurrently incorporating two different types of drugs into a single polymeric nanoparticle …
concurrently incorporating two different types of drugs into a single polymeric nanoparticle …
Klotho: a novel biomarker for cancer
X Zhou, X Wang - Journal of cancer research and clinical oncology, 2015 - Springer
Abstract Background The Klotho gene was originally identified as an anti-aging gene in
1997. Recent studies have demonstrated aberrant expression of Klotho in a number of …
1997. Recent studies have demonstrated aberrant expression of Klotho in a number of …
[HTML][HTML] Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?
Non-small-cell lung cancer (NSCLC) is a leading cause of malignancy-related mortality in
the Western world. Despite advances in early detection and standard treatment, NSCLC is …
the Western world. Despite advances in early detection and standard treatment, NSCLC is …
[HTML][HTML] Use of nanotechnology to develop multi-drug inhibitors for cancer therapy
R Gowda, NR Jones, S Banerjee… - … of nanomedicine & …, 2013 - ncbi.nlm.nih.gov
Therapeutic agents that inhibit a single target often cannot combat a multifactorial disease
such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications …
such as cancer. Thus, multi-target inhibitors (MTIs) are needed to circumvent complications …
MicroRNA let-7a Inhibits the Proliferation and Invasion of Nonsmall Cell Lung Cancer Cell Line 95D by Regulating K-Ras and HMGA2 Gene Expression
Y Wang, T Ren, Y Cai, X He - Cancer Biotherapy and …, 2013 - liebertpub.com
MicroRNAs are closely linked to tumor metastasis and let-7a may play a role in inhibiting the
proliferation, invasion, and metastasis of lung cancer. In vitro, we aim to observe the impact …
proliferation, invasion, and metastasis of lung cancer. In vitro, we aim to observe the impact …
Nanoparticle drug delivery enhances the cytotoxicity of hydrophobic–hydrophilic drug conjugates
We report a drug conjugation approach to concurrently load both hydrophobic and
hydrophilic drugs into the same drug delivery nanocarrier in a precisely controllable manner …
hydrophilic drugs into the same drug delivery nanocarrier in a precisely controllable manner …
Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell …
ZY He, MF Li, JH Lin, D Lin, RJ Lin - Cancer management and …, 2019 - Taylor & Francis
Background Non-small-cell lung cancer (NSCLC) is a global public health problem, and
brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy …
brain is a common metastatic site in advanced NSCLC. Currently, whole-brain radiotherapy …
Multifunctional nanocarriers for simultaneous encapsulation of hydrophobic and hydrophilic drugs in cancer treatment
Combination therapy for cancer patients is an important standard of care protocol because it
can elicit synergistic therapeutic effects and reduce systemic toxicity by simultaneously …
can elicit synergistic therapeutic effects and reduce systemic toxicity by simultaneously …